Sutro Biopharma (STRO) Net Margin (2017 - 2026)
Sutro Biopharma (STRO) posted Net Margin of 708.42% for Q4 2025, down 20.77% sequentially from 586.58% in Q3 2025, and down 21924.0% YoY from N/an in Q4 2024.
Powered by 
Analysis
Sutro Biopharma (STRO) Net Margin (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Net Margin for 9 years, with the latest figure at 708.42% in Q4 2025.
- Quarterly Net Margin fell 21924.0% year-over-year to 708.42% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 187.54% (up 17907.0% YoY) and the FY2025 annual result came in at 186.45%, up 18017.0% from the prior year.
- Net Margin retreated to 708.42% in Q4 2025 per STRO's latest filing, from 586.58% in the prior quarter.
- Over five years, Net Margin peaked at 27.31% in Q4 2023 and troughed at 708.42% in Q4 2025.
- A 5-year average of 326.87% and a median of 366.41% in 2021 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin slumped 52904 bps in 2022, then jumped 42807 bps in 2023.
- Over 5 years, Net Margin stood at 357.85% in 2021, then slipped by 12 bps to 400.76% in 2022, then surged by 107 bps to 27.31% in 2023, then plunged by 1891 bps to 489.18% in 2024, then plunged by 45 bps to 708.42% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 708.42%, 586.58%, and 18.04% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 12.09% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -3.12% |
| 10 | Sutro Biopharma | 332.59 Mn | 168.25 Mn | - | -391.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -391.64% |
| Dec 31, 2025 | -101.62% |
| Sep 30, 2025 | -586.58% |
| Jun 30, 2025 | -18.04% |
| Mar 31, 2025 | -375.45% |
| Dec 31, 2024 | -489.43% |
| Sep 30, 2024 | -572.62% |
| Jun 30, 2024 | -186.80% |
| Mar 31, 2024 | -447.52% |
| Dec 31, 2023 | 27.31% |
| Sep 30, 2023 | -291.21% |
| Jun 30, 2023 | -370.00% |
| Mar 31, 2023 | -394.90% |
| Dec 31, 2022 | -400.76% |
| Sep 30, 2022 | -77.50% |
| Jun 30, 2022 | -92.58% |
| Mar 31, 2022 | -663.22% |
| Dec 31, 2021 | -357.85% |
| Sep 30, 2021 | -362.83% |
| Jun 30, 2021 | -21.93% |